Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)

• Status: Completed
• Trial end date: 2015-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to determine if lipoic acid can protect the brain and slow disability in secondary progressive multiple sclerosis.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: VA Office of Research and Development
• Collaborator: Oregon Health and Science University
• Treatments: Thioctic Acid

Criteria

Inclusion Criteria:

• Diagnosis of SPMS

• Age 40-70 years

• Able to understand English and able to give informed consent

Exclusion Criteria:

• Unable to undergo MRI testing

• For ambulatory subjects only, a self-reported medical or neurological condition other than MS that is a cause of progressive or fluctuating problems that affect walking(e.g. worsening neuropathy, uncontrolled lower extremity arthritis, uncontrolled heart or lung disease)

• For ambulatory subjects only, fixed and/or stable conditions of less than 1 years duration that affect walking (e.g. joint replacement, lumbar stenosis, alcoholism, stroke, etc.)

• Pregnant or breast-feeding.

• Current major disease or disorder other than MS (such as cancer, kidney, heart or lung disease, post-traumatic stress disorder) that may interfere with study procedures

• Natalizumab, mitoxantrone, azathioprine taken in the last 12 months

• Other immunosuppressants or chemotherapies taken in the last 12 months

• Scheduled (every 3 months or more frequently) IV steroids used in the last 12 months

• IV or oral steroids taken in the past 60 days.

• Lipoic acid taken in the past 60 days.

• Subject has insulin-dependent diabetes or is not controlled on oral diabetes medications